Patent US4436741A successfully refreshed from Google Patents.
US4436741A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for administering scopolamine transdermally
Assignee: Alza Corp
•
Filing: 1983-03-14
•
Granted: 1984-03-13
•
Expires: 2003-03-14
Abstract
Abstract Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 μg/cm 2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 μg/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.
Inventors
- 👤 John Urquhart
- 👤 Santosh K. Chandrasekaran
- 👤 Jane E. Shaw
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 07:50
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/46; A61K9/7084; A61M; A61M37/00; A61F; A61F13/00; A61F2013/00361; A61F2013/00544; A61F2013/00646
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
82 words
A method for administering scopolamine transdermally for a prolonged time period comprising administering scopolamine base to a predetermined area of unbroken skin in a skin saturating initial dose of about 10 to about 200 μg/cm 2 of skin and thereafter at a substantially constant rate in the range of about 0.3 to about 15 μg/hr which rate is sufficient to maintain the urinary excretion of scopolamine in the range of from 0.05 to about 1.5 μg/hr for said prolonged period of time.
Claim 2
Independent Claim
82 words
A method for administering scopolamine transdermally for a prolonged time period comprising administering scopolamine base to a predetermined area of unbroken skin in a skin saturating initial dose of about 10 to about 200 μg/cm 2 of skin and thereafter at a substantially constant rate in the range of about 0.3 to about 15 μg/hr which rate is sufficient to maintain the urinary excretion of scopolamine in the range of from 0.05 to about 1.5 μg/hr for said prolonged period of time.
Claim 3
Independent Claim
80 words
A method for administering scopolamine transdermally for a prolonged period of time comprising: (a) administering scopolamine base to a predetermined area of unbroken skin until sufficient scopolamine has been administered to occupy the scopolamine binding sites associated with said area of skin and; (b) after said binding site have been occupied continuously administering scopolamine to said area of skin at a substantially constant rate in the range of about 0.3 to about 15 μg/hr for said prolonged period of time.
Claim 4
Independent Claim
80 words
A method for administering scopolamine transdermally for a prolonged period of time comprising: (a) administering scopolamine base to a predetermined area of unbroken skin until sufficient scopolamine has been administered to occupy the scopolamine binding sites associated with said area of skin and; (b) after said binding site have been occupied continuously administering scopolamine to said area of skin at a substantially constant rate in the range of about 0.3 to about 15 μg/hr for said prolonged period of time.
Claim 5
Dependent Claim
16 words
The method of claim 2 wherein said area of skin is located at the mastoidal area.
Claim 6
Dependent Claim
21 words
The method of claim 2 wherein the scopolamine is administered to the skin of a subject suffering from a vestibular disturbance.
Claim 7
Dependent Claim
25 words
The method of claim 2 wherein the substantially constant rate is about 5 to 15 μg/hr for adults and 3 to 10 μg/hr for children.
Claim 8
Dependent Claim
23 words
The method of claim 3 wherein the substantially constant rate is about 5 to 15 μg/hr for adults and 3-10 μg/hr for children.
Claim 9
Dependent Claim
28 words
The method of claim 5 wherein said scopolamine binding sites are saturated by the administration of a dose of about 10 to about 200 μg/cm 2 of skin.
Claim 10
Dependent Claim
17 words
The method of claim 2 wherein the scopolamine is administered to the skin of a pregnant subject.
Claim 11
Dependent Claim
18 words
The method of claim 2 wherein the scopolamine is administered to the skin of a subject undergoing chemotherapy.
Claim 12
Dependent Claim
19 words
The method of claim 2 wherein the scopolamine is administered to the skin of a subject undergoing radiation therapy.
Claim 13
Dependent Claim
20 words
The method of claim 2 wherein the scopolamine is administered to the skin of a subject treated with an anesthetic.
References Cited (Backward Citations)
US3797494A
Cited
US3996934A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-03-13 | 1987-09-12 | 1988-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-03-13 | 1991-09-12 | 1992-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-03-13 | 1995-09-12 | 1996-03-13 | $7700.00 | Window Closed / Lapsed |